FRANKFURT (dpa-AFX Broker) - After their recent slide, shares of Sartorius stabilized considerably on Thursday morning. The papers of the laboratory and pharmaceutical supplier recovered by up to 8.6 percent to 276 euros. The day before, at 251.50 euros, they had cost less than at any time since May 2020. Since the forecast reduction last Friday, they had lost almost 22 percent.

Now followed on the penultimate trading day of the week the complete quarterly report. JPMorgan expert Richard Vosser positively assessed the surprisingly good order situation in the Bioprocess Solutions (BPS) division. He expects the share price to recover by 5 to 10 percent - also in the shares of the subsidiary Sartorius Stedim Biotech, under whose umbrella the biotechnology business is largely managed. After plummeting 21 percent in the past few days, these shares had already recovered and recently climbed another 7.8 percent./ag/tav